Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nikhil Amin

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
The Journal of Allergy and Clinical Immunology. in Practice|October 18, 2024
Dupilumab Induces Long-Term On-Treatment Clinical Remission in Patients With Type 2 AsthmaIan D Pavord, Klaus F Rabe, Elliot Israel, et al.
ERJ Open Research|September 25, 2024
AERIFY-1/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPDKlaus F Rabe, Fernando J Martinez, Surya P Bhatt, et al.
The Journal of Allergy and Clinical Immunology|March 2, 2024
Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trialsMarcus Maurer, Thomas B Casale, Sarbjit S Saini, et al.
American Journal of Respiratory and Critical Care Medicine|August 2, 2016
Official American Thoracic Society Clinical Practice Guidelines: Diagnostic Evaluation of Infants with Recurrent or Persistent WheezingClement L Ren, Charles R Esther, Jason S Debley, et al.
The New England Journal of Medicine|May 22, 2018
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe AsthmaKlaus F Rabe, Parameswaran Nair, Guy Brusselle, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 16, 2019
Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic AsthmaJonathan Corren, Mario Castro, Thomas O'Riordan, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|June 1, 2020
Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitisWilliam W Busse, Jorge F Maspero, Yufang Lu, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 8, 2022
Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory DiseasesG Walter Canonica, Arnaud Bourdin, Anju T Peters, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|March 23, 2023
Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthmaDaniel J Jackson, Leonard B Bacharier, Wanda Phipatanakul, et al.
Allergy|May 29, 2026
Effect of Dupilumab on Airway Inflammation in Patients With Persistent AsthmaMichael E Wechsler, Sally E Wenzel, Steve D Groshong, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
The Journal of Allergy and Clinical Immunology. in Practice|October 18, 2024
Dupilumab Induces Long-Term On-Treatment Clinical Remission in Patients With Type 2 AsthmaIan D Pavord, Klaus F Rabe, Elliot Israel, et al.
ERJ Open Research|September 25, 2024
AERIFY-1/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPDKlaus F Rabe, Fernando J Martinez, Surya P Bhatt, et al.
The Journal of Allergy and Clinical Immunology|March 2, 2024
Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trialsMarcus Maurer, Thomas B Casale, Sarbjit S Saini, et al.
American Journal of Respiratory and Critical Care Medicine|August 2, 2016
Official American Thoracic Society Clinical Practice Guidelines: Diagnostic Evaluation of Infants with Recurrent or Persistent WheezingClement L Ren, Charles R Esther, Jason S Debley, et al.
The New England Journal of Medicine|May 22, 2018
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe AsthmaKlaus F Rabe, Parameswaran Nair, Guy Brusselle, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 16, 2019
Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic AsthmaJonathan Corren, Mario Castro, Thomas O'Riordan, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|June 1, 2020
Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitisWilliam W Busse, Jorge F Maspero, Yufang Lu, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 8, 2022
Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory DiseasesG Walter Canonica, Arnaud Bourdin, Anju T Peters, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|March 23, 2023
Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthmaDaniel J Jackson, Leonard B Bacharier, Wanda Phipatanakul, et al.
Allergy|May 29, 2026
Effect of Dupilumab on Airway Inflammation in Patients With Persistent AsthmaMichael E Wechsler, Sally E Wenzel, Steve D Groshong, et al.
Pageof 6